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Paediatric research in the times of COVID-19
Paul F. Fleming1,2, Chris Gale3,4, Eleanor J. Molloy5,6,7, Saul N. Faust8, Kate Costeloe2, Edmund Juszczak9 and Charles C. Roehr10,11
The COVID-19 pandemic poses many direct and indirect consequences for children’s health and associated research. Direct
consequences include participation of children in COVID-19 research trials, pausing other research in children and the potential
implications of a global economic downturn on future research funding. Collaborative and networked research together with
streamlined research processes and use of remote technology have been central to efforts by clinicians and scientists around the
world and have proved essential for reducing COVID-19 morbidity and mortality.
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IMPACT:
● Maintain streamlined and efficient approaches to research governance and data sharing to facilitate high-quality collaborative
research.
● Ensure early inclusion of children in trials of therapies for diseases that affect all age groups.
● Paediatric Research Societies should co-ordinate effective processes to define key research questions and develop
multinational clinical trials for diagnostics, therapeutics and preventative strategies for infants, children and young people.
INTRODUCTION
As coronavirus disease 2019 (COVID-19) spread across the globe in
early 2020, healthcare systems adapted urgently to respond to
and understand this newly emerging, highly infectious disease.
COVID-19 in its symptomatic and most severe form primarily affects
adults, particularly the elderly and those with underlying health
conditions.1,2 Children are less severely affected representing <5% of
cases.3–7 However, in May 2020, a severe post-infectious complica-
tion of COVID-19 in children, the paediatric inflammatory multi-
system syndrome temporally associated with COVID-19 (PIMS-TS)
[also known as multisystem inflammatory syndrome in children and
adolescents temporally associated with COVID-19] was described8
and is now recognised as a significant cause of COVID-19-associated
morbidity.9
Although the incidence of symptomatic and of severe COVID-19
is lower in children, the current pandemic has an increasing
number of implications for children’s healthcare and associated
research. This opinion piece explores some of the effects that the
global pandemic has had upon both COVID-19 and non-COVID-19
research in children, including inclusion of children in COVID-19
research studies and the importance of research delivery through
established research networks, how streamlined research
approvals have facilitated rapid evaluations of potential treat-
ments, impacts of pausing non-COVID-19 research in children and
availability and reconfiguration of post-pandemic research fund-
ing and what this might mean for children’s research in the future.
We also looked at some of the positive research developments
and innovations consequent on COVID-19 and recommend
improvements and modifications we should strive to make as a
lasting beneficial legacy of the pandemic.
RESPONDING TO A GLOBAL PANDEMIC
Despite previous warnings, when COVID-19 first emerged,
pandemic disaster preparedness across the world was insuffi-
cient10 as was delivery of children’s health priorities.11 Global
scientific and medical efforts mobilised quickly. These focussed
on epidemiology2 and therapeutic trials to understand the
burden of disease and to find effective treatments for those
individuals who were critically unwell.12 Simultaneously, a range
of studies was undertaken aimed at better understanding
the immune response to infection,13 developing and evaluating
diagnostic tests and treatments that might dampen the harmful
inflammatory responses,14 developing vaccines directed towards
finding a longer-term solution,15 evaluating and comparing
guidance on the appropriate use of personal protective
equipment,16,17 identifying novel COVID-19 variants and asses-
sing their transmissibility18 and evaluating vaccine efficacy
against variants.19 During the first wave, swathes of research
funding and personnel were redeployed to COVID-19 research
studies and, in many cases, the provision of frontline care. Within
children’s healthcare, a number of international collaborations
were quickly formed to share information and optimise safe
delivery of care to children.20–22
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CHILDREN’S INCLUSION IN COVID-19 RESEARCH, VACCINE
EVALUATIONS AND THE ROLE OF RESEARCH NETWORKS
The general assumption that children are less severely affected by
COVID-19 combined with residual historic reluctance to include
children and pregnant women in the early stages of therapeutic
trials has contributed to delays in including these groups in
COVID-19 trials.23,24 This has interrupted evidence-based evalua-
tions of potential COVID-19 treatments for hospitalised children
and for those who present with more severe forms of the disease.
Instead, a standardised approach should be encouraged that best
serves the needs of all patients while systematically improving our
understanding of the effectiveness and safety of interventions.25,26
Recognising the need for children to have access to the same or
similar treatments as adults, children in the United Kingdom
were included in the RECOVERY (Randomised Evaluation of
COVID-19 Therapy) trial. The RECOVERY trial is an adaptive multi-
arm multicentre platform trial evaluating potential treatments for
COVID-1927 and was set up in 9 days, began recruiting patients in
March 2020 and was rolled out in 174 hospitals throughout the UK.
By day 16 of recruitment, the 1000th patient was recruited and by
March 2021, >38,000. With some age-specific protocol modifications
(Version 5), children with respiratory COVID-19 infection were
included from May 2020 and have been allocated to corticosteroid,
antiviral, convalescent plasma and immunomodulatory arms of this
study. Following the emergence of PIMS-TS,28 the RECOVERY trial
protocol was adapted in July 2020 to evaluate potential treatments
for this condition29 using a standardised approach.30 At present, the
PIMS-TS arm of the RECOVERY trial is evaluating corticosteroid and
intravenous immunoglobulin for initial therapies and tocilizumab
and anakinra for children requiring additional immunomodulatory
therapy.
By June 2020, analyses of three principal comparisons in
RECOVERY provided crucial findings on repurposed treatments for
COVID-19, including dexamethasone,12 hydroxychloroquine31 and
lopinavir–ritonavir.32 Subsequent findings on azithromycin33 and
convalescent plasma have also been reported.27 Studies like the
RECOVERY trial are necessary to safely evaluate COVID-19 interven-
tions in children but are few and far between. As of January 2021,
<10% of registered interventional studies in COVID-19 on clinical-
trials.gov included children.
Although children were initially involved in the first protocols
to test pandemic vaccines, the emergence of PIMS-TS made
paediatric vaccine researchers and pharmaceutical companies
delay paediatric enrolment due to concerns that PIMS-TS
pathophysiology may have an antibody-driven component. There
are now large-scale safety data for the first three vaccines to
protect against COVID-19 under evaluation by global regulatory
authorities, none of which shows any suggestion of inflammatory
adverse effects in adults.34–36 Several COVID-19 vaccines are due
to start specific paediatric and teenage dose-finding and safety
trials, together with trials in pregnant women, in early 2021. It is
important that research systems and networks give equal priority
to these trials. Regulatory authorities will need to consider
whether resource-consuming large-scale phase 3 efficacy trials
are necessary once individual vaccines have identified paediatric
dosing and initial safety data in smaller cohorts. To try to minimise
global education disruption in the immediate years to come,
Phase 4 safety trials during large-scale deployment may be more
appropriate, especially if adult trials identify as-yet, unknown
immunological correlates of protection.
Clinical research networks have played an important role
throughout the pandemic. The World Health Organisation
(WHO) ISARIC standardised data collection protocol,37 the
neonatal COVID-19 networks20 and British Paediatric Surveil-
lance Unit6 are some examples of how networks have provided
crucial epidemiological data identifying at-risk patient groups,
informing best clinical practice and identifying priority areas
for critical research delivery. Deployment of studies like the
RECOVERY trial is testament to the UK’s clinical research network
infrastructure38 and well-established public healthcare system,
which allow patient groups across all ages access to clinical
research priority studies.
STREAMLINED RESEARCH APPROVAL
Alongside light-touch streamlined systems that allow for rapid
patient recruitment, consent, randomisation and data collection,39
research systems have evolved even more efficient risk-based
systems for research approval and delivery. The speedy delivery of
studies like the RECOVERY trial was enhanced by embedding the
research in clinical practice, with simple, targeted but effective
staff training and site governance requirements.
Research governance and patient safety are critical but approvals
often have multiple layers of bureaucracy that inevitably slow the
rate at which studies are conducted. In response to COVID-19
treatment evaluations, many countries have introduced stream-
lined approaches to approve research while using remote video
conferencing to convene relevant meetings, such as ethics review
boards. As we move forward, we should learn how the approval
processes can be better aligned to deliver efficient and propor-
tionate regulation while ensuring current levels of patient safety are
maintained. This may require a fundamental re-evaluation and risk
analysis of the way research is conducted alongside routine clinical
care. Research training and governance can certainly be better
targeted in a risk-appropriate way, with more resource and
oversight for complex or higher-risk early phase trials and later
phase trials more embedded in routine clinical care.40
IMPACT OF PAUSING CHILDREN’S RESEARCH
In response to the urgency and severity of the COVID-19 pandemic,
many countries and healthcare systems initially paused non-COVID-
19 clinical research studies.26 Despite children being less severely
affected by COVID-19, this pause involved important studies cross all
paediatric domains including many that had taken years to establish.
There is also an indirect financial burden from pausing research if
this results in delayed dissemination of results that have potential
cost-saving implications.41 In retrospect, these pauses may have
disproportionately and negatively affected children and may have
arisen from gaps in preparedness and limited learning from previous
pandemics11 together with uncertainties about the evolution of the
COVID-19 pandemic.
Furthermore, COVID-19 fundamentally changed the context of
many patient-facing clinical and translational research efforts as a
result of plummeting rates of admission for commonly studied
conditions.42 A reduced disease burden together with limited
research opportunities could derail the research aspirations of
young investigators at a critical point in their career development
and deprive them of the opportunities to conduct research. This,
in turn, may impact the critical mass of experienced paediatric
researchers in the future.
Alternative strategies for maintaining research have been
proposed, including modifications to the consent process,
prioritisation of outcome data collection and exploring alternative
methods of measuring key outcomes (e.g. continuing data
collection remotely or online).43 Such strategies need monitoring
as their impact on the validity of studies remains unclear. Before
2020, contingency measures to account for such a global
pandemic were highly unlikely to be the focus for many
researchers. This is in itself an important lesson in terms of risk
assessment.
When the time came to restart children’s research, the initial
focus was on studies that were already recruiting prior to the
pandemic, quick and efficient progression of those studies
already ‘in set-up’ and supporting paediatric research trainees
whose projects were suspended by the pandemic and who have
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limited time in which to complete their studies. Where possible,
this was done using mechanisms that reduced administration
time and costs, thereby limiting the negative impact of the
pause on research.
As we re-start research, consideration of the wider impact of
COVID-19 on children’s health needs to be evaluated and
researched. There are many areas within children’s health that are
under ongoing scrutiny such as the impacts of isolation on mental
health, child protection issues, COVID-19 severity in children with
chronic diseases, reduced attendance at hospitals,44 healthcare
disparities and how some of these disparities might be mitigated
through better access to telehealth.45 These important areas of
research need further support so that we can understand and
address the impact of COVID-19 on health and wellbeing and are
ready to respond better to future pandemics.
POST-PANDEMIC RESEARCH FUNDING RECONFIGURATION
AND IMPLICATIONS FOR FUTURE CHILDREN’S RESEARCH
Expectedly and appropriately, the pandemic has resulted in a
rapid realignment and unparalleled focus on COVID-19 research.
Effective treatment and prevention of COVID-19 are essential at
an individual and societal level, as a healthy workforce is the
cornerstone of a thriving economy, which in turn underpins
current and future research activity. Most research funders have
acted rapidly and flexibly to support existing research impacted
by COVID-19. However, the funding landscape for future research,
particularly research not focused on COVID-19, is highly uncertain,
at least in the short to medium term. Charity funding for health
research has been severely affected by the pandemic. One
example is The Association of Medical Research Charities in the
UK, who warned that their ability to fund research may fall by over
£300 million in 2020 as a result of the impact of COVID-19 on
fundraising activities.46 This will have widespread impacts on
fundamental research, clinical trials, research infrastructure and on
research fellowships and other individual support at all career
stages. Furthermore, the pandemic has caused a significant
contraction in the global economy, which will almost certainly
lead to lower government funding of medical research in some
countries.
Such systematic changes to the research funding landscape will
inevitably impact paediatric research, which was already under-
represented relative to other age groups and disease areas prior to
COVID-19.47,48 Children have been disproportionately affected by
responses to the COVID-19 pandemic, for instance by school
closures in lockdown and entire year groups or “bubbles” spending
time in self-isolation due to case identification in schools when
open. To ensure that paediatric research is not overly impacted
post-pandemic, we, as paediatric researchers and clinician scientists,
must advocate for the importance of such research to improve the
future health and wealth of nations. The UK Children’s Charter
highlights the importance of equity between children’s and adult
research and now, more than ever, preventing conditions such as
obesity and hypertension in childhood is particularly pertinent as
these conditions predispose to severe disease among adults
affected by COVID-19 (https://www.rcpch.ac.uk/resources/research-
charter-infants-childrens-young-peoples-child-health).
WHAT ARE THE POSITIVE OUTCOMES TO EMERGE FROM THE
COVID-19 PANDEMIC?
Several positive outcomes for children’s research have arisen
during this period. One has been recognition from across the
research spectrum that rapid, responsive collaboration can be
achieved and is essential to effectively and quickly address
important clinical questions. Examples of these collaborations
include epidemiological studies allowing better understanding of
COVID-19 infection in children,5 defining core outcomes for
assessment in clinical trials so that meaningful streamlined data
can be collected49,50 and for sharing and collating guidelines for
specific populations, such as newborn babies.20,51 These global
collaborations are a credit to the efforts of researchers to bring
knowledge and best available practice together and to dissemi-
nate it quickly and efficiently via social media and online
collaboration.52
The second is the recognition that study design may not need
multiple complex layers of administration and that approval
processes can be streamlined without compromising quality and
safety. Necessary remote working and use of video conferencing
technology has allowed people to become familiar with conduct-
ing meetings, delivering teaching, attending seminars and even
conferences from multiple locations across the world. The online
summer series provided by the Pediatric Academic Society or the
fully virtual European Academic Paediatric Societies meeting are
just two examples of how important forums for researchers can be
adapted to facilitate dissemination and discussion of results from
clinical trials and research studies remotely to influence current
clinical practice within a global pandemic.
The use of technology has facilitated more rapid identification
platforms and early warning systems for emerging diseases like
PIMS-TS and allowed paediatric experts from across the world to
collaboratively and quickly reach agreed consensus on case
definitions and treatment protocols.50 Routinely collected electro-
nic patient data with standardised definitions of outcomes are
used increasingly to compare neonatal services53 and access to
such data that are not dependent on conventional, often
cumbersome, methods of data collection paves the way to
streamlining data collection for clinical trials. Finally, the success of
research networks may allow us to reconsider how best we can
collaborate and establish international paediatric networks to
address clinically important questions about children’s health and
disease and thereby accelerate recruitment and generalisability of
results.
One of the most important outcomes from this pandemic
relates to the widespread rollout of novel vaccines, which will
hopefully prove safe and effective in ongoing and future
paediatric trials.54 Furthermore, during COVID-19 vaccine research,
local networks and pharmaceutical companies have established
new systems such as allowing one organisation (one legal entity)
to handle all contracting and governance for contract commercial
research protocols opening in multiple sites and organisations.
Such systems have proved efficient and cost-effective and should
be a lasting benefit of the pandemic on the partnership between
industry and health systems. COVID-19 experience has shown that
contract commercial research organisations will need to adapt or
be rapidly left behind in the emerging post-COVID-19 world.
The European Society for Paediatric Research (ESPR) and the
Society for Pediatric Research are examples of hubs where
paediatric clinical researchers meet, share and disseminate research
findings. The ESPR has advanced numerous paediatric COVID-19
research collaborations and research mentoring schemes (www.
espr.eu). Thus, societies have taken a pivotal role in forging and
fostering international collaborations to coordinate bench-top
research and acute COVID-19 clinical guideline development and
knowledge exchange from the start of the pandemic.20,52,55–57 In
light of the current pandemic and in preparation for the next, such
societies are well placed to become perhaps the most important
providers of platforms for forming such networks and for
coordinating public patient involvement.58,59
WILL THE COVID-19 PANDEMIC AFFECT THE WAY WE
CONDUCT CHILDREN’S RESEARCH IN THE FUTURE?
Social science often uses the terms ‘generation’ and ‘birth cohorts’
synonymously to refer to ‘people within a delineated population
who experience the same significant events within a given time
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period’.60 Historically these ‘generations’ include the Baby
Boomers, Generation X and Millennials and perhaps now, in the
context of the current global pandemic, Generation COVID (Gen
C). Generation C is likely to experience a wide variety of health
consequences. These consequences will inevitably influence the
way we conduct children’s research in the future. Platform trials
might be a means by which pragmatic trials are conducted in
certain paediatric populations, such as newborn babies. We
should ensure that we shape health research agendas now so
that children remain at the forefront of current clinical research
priorities. In order to achieve the right outcomes for children,
paediatric researchers should harness the positive advances while
leaving behind the negative impact this pandemic has exerted on
children’s research.
CONCLUSION
With encouraging updates from potentially successful vaccines
against COVID-19,61–63 a path to the end of this pandemic is
visible. To achieve better outcomes for children’s healthcare
research, even stronger international networks and collaborations
need to be developed and fostered. Paediatric researchers must
continue to raise the profile of their research, to streamline
research design and approvals and to create new relationships
and ways of working with industry to allow fast and pragmatic
deployment of research to address the ever-important health
needs of children. In doing so, the positive outcomes learned
during this pandemic can create a better platform for children’s
research as we move forward.
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